Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial
Posted inHematology-Oncology news Oncology

Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial

The phase 3 GEM12 trial compares busulfan-melphalan versus melphalan conditioning in ASCT for newly diagnosed multiple myeloma, showing longer PFS with busulfan-melphalan after intensified VRD induction and consolidation, especially in advanced ISS stages and select genetic subgroups.
Posted inClinical Updates Hematology-Oncology news Specialties

Enhanced Progression-Free Survival with Ibrutinib Plus Rituximab in CXCR4-Mutated Waldenström Macroglobulinemia: Insights from a Pooled Analysis

A pooled analysis of prospective studies shows ibrutinib plus rituximab improves progression-free survival in Waldenström macroglobulinemia patients with CXCR4 mutations compared to ibrutinib alone, supporting routine CXCR4 testing and combination treatment strategies.
Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study
Posted inClinical Updates Hematology-Oncology Specialties

Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study

Maintenance therapy with romidepsin following autologous hematopoietic stem-cell transplantation (AHCT) in peripheral T-cell lymphoma (PTCL) demonstrated feasibility and an estimated 2-year progression-free survival (PFS) of 62%, though the primary efficacy endpoint was not met in this phase 2 trial.
Oral Realgar-Indigo Naturalis Formula Matches Arsenic Trioxide Efficacy in Non-High-Risk Acute Promyelocytic Leukemia: Insights from a Multicenter Randomized Trial
Posted inClinical Updates Hematology-Oncology Specialties

Oral Realgar-Indigo Naturalis Formula Matches Arsenic Trioxide Efficacy in Non-High-Risk Acute Promyelocytic Leukemia: Insights from a Multicenter Randomized Trial

A pivotal multicenter randomized trial demonstrates that oral Realgar-Indigo naturalis formula (RIF) combined with ATRA is non-inferior to arsenic trioxide (ATO) plus ATRA, providing a simplified consolidation regimen for non-high-risk APL with excellent 2-year disease-free survival and manageable toxicity.